Search the Newsreel

Panther Metals Sells Northern Territory Lease to Fund WA Focus

Dianthus Therapeutics, Inc. Stock 12‑Month Price Target Raised to $133.79, Implies 21% Upside

The average 12-month price target for Dianthus Therapeutics, Inc. (DNTH) stock has increased from $129.77 to $133.79, according to 14 analysts. This updated target suggests a potential upside of approximately 21% from its August 4th closing price. The consensus rating for DNTH remains a …

Lantheus Holdings Inc earnings beat by $0.26, revenue topped estimates

Lantheus Holdings Inc (LNTH) reported strong second-quarter results, beating analyst expectations for both EPS and revenue. The company announced an EPS of $1.55 against an estimate of $1.29, and revenue of $388.2 million, surpassing the consensus of $362.32 million. LNTH's stock has shown significant …

HC Wainwright Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

HC Wainwright has increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) from $130 to $158, maintaining a "buy" rating and suggesting a 40% upside. Despite a positive consensus from analysts, Weiss Ratings reiterated a "sell" rating. The company reported a quarterly loss of $0.90 …

DIANTHUS THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $158 FROM $130

H.C. Wainwright has increased its target price for Dianthus Therapeutics, Inc. (DNTH.O) to $158 from the previous $130. This update was reported by Reuters on August 6, 2026. The article highlights this specific financial analyst action regarding the biotechnology company.

Barinthus Biotherapeut reports Q2 2026 net loss $10.6M, cash $59.6M; VTP-1000 MAD data due Q4 2026

Barinthus Biotherapeutics reported a Q2 2026 net loss of $10.6 million and held $59.6 million in cash. The company completed enrollment for the VTP-1000 Phase 1 AVALON trial's multiple ascending dose portion, with topline data expected in Q4 2026. A proposed combination with Clywedog …

Barinthus Biotherapeutics plc. 2026: Revenue ($9.78M), Net income ($10.58M), EPS ($0.26) — 10-Q Summary

Barinthus Biotherapeutics plc. (BRNS) reported a narrower comprehensive loss in the 2026 quarter, driven by cost reductions and pipeline reprioritization towards immunology and inflammation programs. The company also completed enrollment for a Phase 1 clinical trial and entered a merger agreement with Clywedog, with …

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

Barinthus Bio announced its second quarter 2026 financial results and provided updates on corporate developments, including the progressing proposed combination with Clywedog Therapeutics Inc. The company completed enrollment for the Phase 1 AVALON trial of VTP-1000 for celiac disease, with topline data expected in …

Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026

Lantheus Holdings (NASDAQ:LNTH) reported strong Q2 CY2026 results, exceeding Wall Street expectations with revenue of $388.2 million and non-GAAP EPS of $1.55. Despite impressive five-year revenue and EPS growth, recent performance shows a slowdown, with analysts projecting a revenue decline for the next 12 …

Earnings Flash (LNTH) Lantheus Holdings, Inc. Reports Q2 Revenue $388.2M, vs. FactSet Est of $363.2M

Earnings Flash (LNTH) Lantheus Holdings, Inc. Posts Q2 Adjusted EPS $1.55 per Share, vs. FactSet Est of $1.30

Lantheus Holdings, Inc. (LNTH) reported Q2 adjusted EPS of $1.55 per share, surpassing the FactSet estimate of $1.30. The company also announced its Q2 revenue of $388.2 million, exceeding the FactSet estimate of $363.2 million. Additionally, Lantheus suspended its previously issued full-year 2026 financial …

Lantheus Reports Second Quarter 2026 Financial Results

Lantheus Holdings, Inc. Worldwide revenue of $388.2 million in the second quarter of 2026 GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 Adjusted fully diluted earnings per share of $1.55, compared to $1.57 in the …

Lantheus Holdings: Q2 Earnings Snapshot

Lantheus Holdings Inc. reported strong second-quarter earnings, surpassing Wall Street expectations. The diagnostic imaging company posted a profit of $1.11 per share and adjusted earnings of $1.55 per share, exceeding analyst estimates of $1.33. Revenue for the quarter also beat forecasts, coming in at …

Lantheus' Q2 Adjusted Earnings Fall, Revenue Rises

Lantheus (LNTH) reported a decrease in its Q2 adjusted earnings per diluted share to $1.55, although the company saw an increase in its revenue for the same quarter. The article notes that further details are available for premium subscribers.

Northrop Grumman Corp (NOC) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Pantheon Resources Plc (OTC: PTHRF) Stock Price, News & Analysis

Dianthus Therapeutics (NASDAQ:DNTH) Given New $122.00 Price Target at Wedbush

Wedbush has increased its price target for Dianthus Therapeutics (NASDAQ:DNTH) to $122.00 from $105.00, reiterating an "outperform" rating, which suggests a potential 10% upside. This comes despite the company missing quarterly EPS estimates with a loss of $0.90 per share, though revenue exceeded expectations. …

Gentherm (THRM) plans $882M all-stock merger for Modine’s Performance Technologies arm

Earnings To Watch: Lantheus (LNTH) Reports Q2 Results Tomorrow

Dianthus Therapeutics (NASDAQ:DNTH) Posts Earnings Results, Misses Expectations By $0.05 EPS

Dianthus Therapeutics (NASDAQ:DNTH) reported a quarterly loss of $0.90 per share, missing analyst expectations by $0.05, despite revenue of $0.76 million exceeding the consensus estimate of $0.30 million. Following the announcement, shares rose 4.6% to $110.92. Analysts maintain a "Moderate Buy" rating with an …

Earnings Flash (DNTH) Dianthus Therapeutics, Inc. Reports Q2 License Revenue $761K

Dianthus Therapeutics, Inc. (DNTH) announced Q2 license revenue of $761K. The company is a clinical-stage biotechnology firm focused on therapies for severe autoimmune diseases, with its lead candidate, claseprubart, in Phase 3 trials. Analysts currently have a "BUY" consensus rating for DNTH with an …

Dianthus Therapeutics Q2 net loss widens as R&D costs rise

Dianthus Therapeutics reported a widened Q2 net loss of $50.2 million due to increased operating expenses, primarily driven by higher R&D costs for its clinical programs. Despite the loss, the company ended Q2 with $1.2 billion in cash, expected to fund operations into 2030, …

Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases

Dianthus Therapeutics has announced DNTH312, a new first-in-class, next-generation bifunctional fusion protein aimed at treating severe autoimmune diseases. This investigational drug combines claseprubart and TACI, targeting both active C1s and BAFF/APRIL pathways to provide comprehensive inhibition of B cell activity and Classical Pathway inflammation. …

Synthomer (LON:SYNT) Releases Quarterly Earnings Results

Synthomer H1 Earnings Call Highlights

Key Points Interested in Synthomer plc? Here are five stocks we like better. Synthomer delivered a stronger-than-expected first half, with revenue up 6.7%, EBITDA up 13% and margins expanding to 10.1%. Growth was driven by specialty products, cost actions and supply-chain disruption benefits. The …

Curium to acquire Lantheus in all-cash deal worth up to $8bn

CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn. The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per …

LightInTheBox Holding Co., Ltd. Sponsored ADR Revenue Breakdown – MUN:L4X

LightInTheBox Holding Co., Ltd. Sponsored ADR (MUN:L4X) generated €190.97 million in revenue last year. The Product Sales segment was the highest-performing, bringing in €525.53 million, an increase from €235.41 million in the prior year. Europe was the largest regional contributor, accounting for €266.97 million …

Anthem Biosciences shares gain over 2% today

Synthomer (LON:SYNT) Earns "Buy" Rating from Peel Hunt

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Anthem Biosciences shares decline 2.19% on Tuesday

Earnings Flash (SYNT.L) Synthomer plc Posts H1 Loss GBX-3.1

Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Lantheus Holdings, Inc. (NASDAQ: LNTH) following its recently announced transaction with Curium, questioning if the deal provides a fair price for public shareholders. Lantheus shareholders are set to receive $102.50 per share in cash, plus Contingent Value Rights potentially worth …

Lantheus (LNTH) Agrees To Join Curium In Radiopharmaceuticals Deal

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Curium has entered into a definitive agreement to acquire Lantheus Holdings (NasdaqGM:LNTH) in a transaction that will combine their radiopharmaceutical businesses. The deal …

Dianthus Therapeutics grants stock options to s...

Dianthus Therapeutics has granted 87,000 stock options to six new non-executive employees. These options, with a 10-year term and an exercise price of $106.02 per share, vest over four years and were approved under Nasdaq rules to incentivize new hires. Dianthus is a clinical-stage …

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Dianthus Therapeutics, Inc. has announced the issuance of inducement grants to six newly-hired, non-executive employees on August 3, 2026. These grants, approved by the Company's independent Compensation Committee, consist of non-qualified stock options to purchase an aggregate of 87,000 shares of common stock with …